Sienna Gestion Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Sienna Gestion increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 202.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,499 shares of the biopharmaceutical company’s stock after acquiring an additional 1,004 shares during the quarter. Sienna Gestion’s holdings in Regeneron Pharmaceuticals were worth $1,154,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. WPG Advisers LLC lifted its stake in Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 25 shares during the period. Board of the Pension Protection Fund bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth $31,000. Entrust Financial LLC bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth $32,000. MCF Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 15 shares in the last quarter. Finally, Transamerica Financial Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 380.0% in the fourth quarter. Transamerica Financial Advisors LLC now owns 48 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 38 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Barclays reduced their price target on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Piper Sandler reduced their price target on Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating for the company in a report on Monday, May 18th. Royal Bank Of Canada reduced their price target on Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating for the company in a report on Monday, May 18th. Cantor Fitzgerald restated an “overweight” rating and set a $800.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, April 23rd. Finally, BMO Capital Markets reduced their price target on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a report on Monday, May 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $792.65.

Regeneron Pharmaceuticals Trading Up 0.5%

Regeneron Pharmaceuticals stock opened at $614.98 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. Regeneron Pharmaceuticals, Inc. has a one year low of $503.25 and a one year high of $821.11. The stock has a market capitalization of $65.02 billion, a PE ratio of 14.98, a price-to-earnings-growth ratio of 1.34 and a beta of 0.25. The business’s fifty day moving average is $689.17 and its 200 day moving average is $736.78.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating the consensus estimate of $8.91 by $0.56. The company had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.Regeneron Pharmaceuticals’s revenue was up 19.0% compared to the same quarter last year. During the same period last year, the firm posted $8.22 earnings per share. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were given a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.16%.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director directly owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. This trade represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.